Davis Polk advised the representatives of the underwriters, in connection with the offering of $4.5 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were offered in four tranches, maturing in 2026, 2030, 2040 and 2050.
Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.
The Davis Polk capital markets team included partner Byron B. Rooney and associates Amy Mao and Wendy Li. The tax team included partner Michael Farber and associate Ben Levenback. All members of the Davis Polk team are based in the New York office.